Arcutis Biotherapeutics (ARQT) vs Parabilis Medicines (PBLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Parabilis Medicines is the larger company by market cap ($3.47 billion vs $3.08 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARQT | PBLS |
|---|---|---|
| Share price | $24.49 | $28.09 |
| Market cap | $3.08B | $3.47B |
| 1-day change | +1.32% | -2.53% |
| YTD return | -16.77% | — |
| 1-year return | +17.50% | — |
| 5-year return | +8.48% | — |
| P/E ratio (TTM) | 111.32 | — |
| Forward P/E | 18.01 | — |
| EPS (TTM) | $0.22 | $-9.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $376.07M | — |
| Revenue growth (YoY) | +91.34% | — |
| Net income (latest FY) | $-16.14M | — |
| Gross margin | 90.24% | — |
| Operating margin | -3.25% | — |
| Net margin | -4.29% | — |
| 52-week high | $31.77 | $42.49 |
| 52-week low | $19.30 | $24.51 |
| Distance from 52-week high | -22.91% | -33.89% |
| Analyst consensus | none | none |
| Avg. price target upside | +51.08% | +48.63% |
| Average volume | 2.22M | 675.43K |
| Shares outstanding | 125.69M | 121.95M |
| Employees | 354 | 145 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Arcutis Biotherapeutics
ARQT stock →Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 354 employees
About Parabilis Medicines
PBLS stock →Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment.
Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees
ARQT vs PBLS FAQ
Which is bigger, Arcutis Biotherapeutics or Parabilis Medicines?
Parabilis Medicines (PBLS) is larger, with a market capitalization of $3.47B compared with $3.08B for Arcutis Biotherapeutics (ARQT).
Are Arcutis Biotherapeutics and Parabilis Medicines in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.